AC
KPTI icon

Ascend Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Ascend Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-8,319
Closed -$1.31M – 165
2015
Q3 		$1.31M Sell
8,319
-1,665
-17% -$445K 0.05% 112
2015
Q2 		$4.08M Buy
+9,984
New +$4.32M 0.13% 120

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ascend Capital's KPTI Position: Q4 2015 in Review

Ascend Capital sold out of Karyopharm Therapeutics (KPTI) in Q4 2015, closing a stake of 8,319 shares — an estimated $1.31M sold.

Ascend Capital first reported a position in KPTI in Q2 2015 and held it in 2 quarters. The position peaked at $4.08M in Q2 2015. 85 funds tracked by Wall St. Rank hold KPTI as of Q4 2015.

  • Ascend Capital reported no remaining Karyopharm Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Ascend Capital sold 8,319 Karyopharm Therapeutics shares in Q4 2015, an estimated $1.31M.
  • Ascend Capital first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 2 quarters.
  • Ascend Capital's Karyopharm Therapeutics position peaked at $4.08M in Q2 2015.
  • 85 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2015.

Based on Ascend Capital's 13F filing for Q4 2015, filed 12 Feb 2016.